

Yuanyuan Kong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3634026/publications.pdf>

Version: 2024-02-01

44
papers

640
citations

706676

14
h-index

759306

22
g-index

46
all docs

46
docs citations

46
times ranked

831
citing authors

#	ARTICLE	IF	CITATIONS
1	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. <i>Hepatology International</i> , 2022, 16, 1-23.	1.9	45
2	Clinical characteristics and genetics analysis for the ITD of congenital hypothyroidism. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2022, .	0.4	0
3	Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 420-428.	0.7	5
4	A High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1009-1019.e11.	2.4	13
5	Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1423-1434.	1.4	45
6	Screening varices in patients with HBV-related cirrhosis on antiviral therapy: Platelet alone or together with LSM. <i>Liver International</i> , 2021, 41, 369-377.	1.9	4
7	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2499-2513.	2.4	26
8	Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 611-620.	1.9	7
9	Novel Gross Deletion Mutations in NTRK1 Gene Associated With Congenital Insensitivity to Pain With Anhidrosis. <i>Frontiers in Pediatrics</i> , 2021, 9, 638190.	0.9	6
10	Blood transcriptome profiling as potential biomarkers of suboptimal health status: potential utility of novel biomarkers for predictive, preventive, and personalized medicine strategy. <i>EPMA Journal</i> , 2021, 12, 103-115.	3.3	18
11	Risk of Transmitting Coronavirus Disease 2019 During Nebulizer Treatment: A Systematic Review. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2021, 34, 155-170.	0.7	8
12	C4OH is a potential newborn screening marker—a multicenter retrospective study of patients with beta-ketothiolase deficiency in China. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 224.	1.2	3
13	é—ä¼€ŒŒ...ªº“é...è¡€ç—łłžłřšš...ŕçœŸŕá'Œè~šæ²»èŸłá±•. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medicine</i>		
14	Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 16, 100249.	1.3	11
15	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. <i>Scandinavian Journal of Public Health</i> , 2020, 48, 233-239.	1.2	4
16	Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. <i>Hepatology International</i> , 2020, 14, 105-114.	1.9	31
17	Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. <i>Journal of Digestive Diseases</i> , 2020, 21, 519-525.	0.7	11
18	Circular RNA circCTNNA1 promotes colorectal cancer progression by sponging miR-149-5p and regulating FOXM1 expression. <i>Cell Death and Disease</i> , 2020, 11, 557.	2.7	38

#	ARTICLE	IF	CITATIONS
19	High-Throughput Sequencing Reveals the Loss-of-Function Mutations in GALT Cause Recessive Classical Galactosemia. <i>Frontiers in Pediatrics</i> , 2020, 8, 443.	0.9	2
20	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. <i>OMICS A Journal of Integrative Biology</i> , 2020, 24, 415-423.	1.0	9
21	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2582-2591.e6.	2.4	57
22	Clinical, biochemical and molecular spectrum of mild 6-pyruvoyl-tetrahydropterin synthase deficiency and a case report. <i>Fetal and Pediatric Pathology</i> , 2020, 40, 1-10.	0.4	3
23	Diagnosis of chronic stage of hypertensive retinopathy based on spectral domain optical coherence tomography. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1247-1252.	1.0	4
24	Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cutoff to assess fibrosis stages. <i>Journal of Digestive Diseases</i> , 2020, 21, 279-286.	0.7	6
25	Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients. <i>Computational and Mathematical Methods in Medicine</i> , 2019, 2019, 1-8.	0.7	12
26	Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-12.	0.7	16
27	A multimodal international collaborative clinical research training program in China. <i>Medical Education Online</i> , 2019, 24, 1679944.	1.1	1
28	Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis. <i>Hepatology International</i> , 2019, 13, 788-799.	1.9	44
29	Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. <i>Hepatology International</i> , 2019, 13, 766-776.	1.9	25
30	Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. <i>Journal of Digestive Diseases</i> , 2019, 20, 467-475.	0.7	6
31	Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1676-1684.	1.4	46
32	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. <i>JAMA Oncology</i> , 2019, 5, 915.	3.4	2
33	Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 745-757.	1.1	11
34	Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. <i>Journal of Viral Hepatitis</i> , 2019, 26, 576-585.	1.0	19
35	Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1236-1241.	1.4	15
36	Distribution-free models for latent mixed population responses in a longitudinal setting with missing data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3273-3285.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-7.	0.7	8
38	Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. <i>International Journal of Infectious Diseases</i> , 2018, 67, 58-64.	1.5	6
39	On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis. <i>Liver International</i> , 2018, 38, 1045-1054.	1.9	29
40	Early-life exposure to air pollutants and adverse pregnancy outcomes: protocol for a prospective cohort study in Beijing. <i>BMJ Open</i> , 2017, 7, e015895.	0.8	9
41	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. <i>Scientific Reports</i> , 2016, 6, 37498.	1.6	13
42	Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense. <i>Hepatology International</i> , 2016, 10, 239-241.	1.9	2
43	A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 10039-10055.	1.2	16
44	Incorrect Calculation and Inappropriate Interpretation: Accuracy of International Guidelines for Identifying Significant Fibrosis in Antigen-Negative Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1407-1409.	2.4	1